PRO- AND ANTI-INFLAMMATORY CYTOKINE PROFILES (IL-6, TNF-Α, IL-10) IN INFLAMMATORY BOWEL DISEASE AND RHEUMATOID ARTHRITIS: A COMPARATIVE CLINICAL STUDY
Main Article Content
Keywords
Ureteral stone, Holmium YAG laser, Pneumatic lithotripsy, Lithotripsy efficacy, Stone migration
Abstract
Background: Inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) are chronic immune-mediated inflammatory disorders characterized by dysregulated cytokine networks. While both conditions share common inflammatory pathways, comparative analyses of cytokine profiles between these diseases remain limited. Understanding differential cytokine expression may provide insights into disease-specific pathogenesis and therapeutic targeting.
Methods: This cross-sectional comparative study enrolled 200 participants: 60 patients with inflammatory bowel disease (30 Crohn's disease, 30 ulcerative colitis), 60 patients with rheumatoid arthritis, and 80 age- and sex-matched healthy controls. Serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10) were measured using enzyme-linked immunosorbent assay. Disease activity was assessed using standardized indices. Statistical comparisons utilized ANOVA, independent t-tests, and correlation analyses.
Results: Both IBD and RA patients demonstrated significantly elevated pro-inflammatory cytokines compared to controls. IL-6 levels were highest in RA patients (42.68 ± 18.74 pg/mL) followed by IBD (28.94 ± 12.36 pg/mL) and controls (6.82 ± 3.14 pg/mL) (p<0.001). TNF-α levels were comparable between IBD (34.52 ± 14.28 pg/mL) and RA (31.86 ± 13.42 pg/mL), both significantly exceeding controls (8.24 ± 3.68 pg/mL) (p<0.001). IL-10 levels were reduced in both disease groups compared to controls (p<0.001). The IL-6/IL-10 ratio was significantly higher in RA (4.82 ± 1.94) versus IBD (3.24 ± 1.56) (p<0.001).
Conclusion: Distinct cytokine signatures exist between inflammatory bowel disease and rheumatoid arthritis, with IL-6 predominance in RA and comparable TNF-α elevation in both conditions. These differential profiles may guide personalized therapeutic approaches in immune-mediated inflammatory diseases.
References
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347(6):417-29. DOI: 10.1056/NEJMra020831
3. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-42. DOI: 10.1038/nri2094
4. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549. DOI: 10.1146/annurev.immunol.20.100301.064816
5. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440. DOI: 10.1146/annurev.immunol.14.1.397
6. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765. DOI: 10.1146/annurev.immunol.19.1.683
7. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-96. DOI: 10.1146/annurev.immunol.19.1.163
8. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340(18):1398-405. DOI: 10.1056/NEJM199905063401804
9. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619-26. DOI: 10.1038/ncprheum0338
10. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75(2):263-74. DOI: 10.1016/0092-8674(93)80068-P
11. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics. 1997;46(2):120-8. DOI: 10.1007/s002510050250
12. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8 Suppl 2:S3. DOI: 10.1186/ar1917
13. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-42. PMID: 24751956
14. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907-16. DOI: 10.1056/NEJM200103223441207
15. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2(6):473-88. DOI: 10.1038/nrd1109
16. Kishimoto T. Interleukin-6: from basic science to medicine—40 years in immunology. Annu Rev Immunol. 2005;23:1-21. DOI: 10.1146/annurev.immunol.23.021704.115806
17. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731-40. DOI: 10.1016/j.intimp.2005.05.010
18. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761-9. DOI: 10.1002/art.20303
19. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537-45. DOI: 10.1172/JCI36389
20. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. DOI: 10.1056/NEJMoa050516
21. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5(2):119-33. DOI: 10.1097/00054725-199905000-00008
22. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy—review of a new approach. Pharmacol Rev. 2003;55(2):241-69. DOI: 10.1124/pr.55.2.4
23. Tilg H, van Montfrans C, van den Ende A, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002;50(2):191-5. DOI: 10.1136/gut.50.2.191
24. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25(3):247-55. DOI: 10.1111/j.1365-2036.2006.03184.x
25. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426-31. DOI: 10.1136/gut.2005.069476
26. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861-74. DOI: 10.1016/S0140-6736(07)60784-3
27. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354(9194):1932-9. DOI: 10.1016/S0140-6736(99)05246-0
28. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997;337(15):1029-35. DOI: 10.1056/NEJM199710093371502
29. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4
30. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-98. DOI: 10.1146/annurev.med.51.1.289.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Rashmi Verma
Assistant Professor Department of General Medicine, Santosh medical college and hospital, Ghaziabad, NCR Delhi.
